Statistical analysis method recommendations for in vitro nonprofile bioequivalence data, to accompany the draft guidance for industry entitled Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action (April 2, 2003), are under development. At a later time, the analysis methods will be posted. Until these methods are prepared, two documents, both in need of updating, are being made available in the present document. These documents are the original statistical information taken from the earlier June 1999 draft of this guidance, and also from the added Statistical Information for In Vitro Bioequivalence Data material posted on August 18, 1999. The subsequent implementation will include the estimation of within canister (between life stage) component of variance.
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.